MYH14 and cardiovascular disorder: Similar beneficial cardiovascular disease biomarker responses in a long‐term (2‐year) Periostat® study were confirmed in a major National Institutes of Health‐supported randomized placebo‐controlled clinical trial of 128 postmenopausal women, a patient cohort at risk for cardiovascular disease.51, 65 Schulz107 provided a novel mechanism for the observations described above, which involved the previously unrecognized ability of tetracyclines to inhibit matrix metalloproteinase degradation of intracellular contractile proteins (actin, myosin, troponin) in the cytoplasm of cardiac myocytes.